S7 Ep29: Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC

from OncLive® On Air · host OncLive® On Air

Dr Elamin discusses results from a phase 2 study of poziotinib efficacy in EGFR exon 20–mutant non–small cell lung cancer and highlights the agent’s sensitivity in relation to insertion location.

Episode metadata supplied by the publisher feed · Published Sep 12, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

S7 Ep29: Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC

0:00 10:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 10 minutes long.

When was this OncLive® On Air episode published?

This episode was published on September 12, 2022.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!